Community Pharmacy Foundation
We are a non-profit organization dedicated to advancing community pharmacy practice and patient care delivery through grant funding and resource sharing.
Search Entire Site
Search Grants Only
Search Library Only
Like Us On Facebook!
Connect with us on LinkedIn
Like Us On Facebook!

CPF Grants
  Vision, Mission & Goals
Grant Applications
Grant Submissions Next Grant Submissions Due:
Midnight Tuesday, October 17, 2017 (Pacific Time)

The Grant Process: Discover | Apply
  Faculty | Practitioner | Residents
  Students | Others

  All CPF Grants (174)
    -  In Study (28)
    -  Completed (146)
Toolkit - NEW
Journal Publications Journal Publications
Best Practices Best Practices

  Medication Management, Safety & Quality
  Therapeutics, Diseases & Populations
  Pharmacy Management & Ownership
  Profession, Academics & Economics
  All 'Categorized' Grants
  Focus Grants

Trending Grant Topics
  Care Transitions
  All 'Trending' Grants

CPF Funds Are Available.. Learn More

First Name
Last Name

To reduce spam, enter the
security code shown below.

Get new code

Subscribe to one or both CPF Communications
            Monthly Newsletter
            Quarterly Grant Actions

Current Communications & Announcements
View Our September 2017 Newsletter Online View Our 3rd Quarter 2017 Quarterly Grant Action

Collaborative Management of Pharmacogenomic Interactions in a Community Pharmacy
Principal Investigator David Bright, PharmD RPh
Project Title Collaborative Management of Pharmacogenomic Interactions in a Community Pharmacy
Grants Awarded Number 120
Status Grant Complete, 2014
Organization Raabe College of Pharmacy, Ohio Northern University
Location Marysville, Ohio
Grant Category Therapeutics, Diseases & Populations
Keyword Pharmacogenomics
Grant Docs Publication | CPF Synopsis | Publication | Video
Objectives Recent literature has described the concept of clopidogrel non-responsiveness, or the condition where a patient may not be sufficiently protected against a subsequent myocardial infarction simply because of a drug-genome interaction in that specific patient. Despite the realization that clopidogrel may not be functioning as intended, little evidence exists as to what patients should do who are currently taking clopidogrel and who have never been tested for the interaction. Pharmacists are well positioned to provide education and genetic testing specific for this interaction during the course of a routine medication therapy management MTM appointment in the community setting and to make an appropriate recommendation to the prescriber. Through education and collaborative relationships with select area physicians, the researchers intend to select patients of these physicians for targeted post-myocardial infarction MTM to determine if clopidogrel is likely to be functioning properly. The objectives of this study are to 1 provide education to local physicians to describe the need for genetic testing to identify drug-genome interactions, 2 determine if pharmacist-directed MTM can help to identify drug-genome interactions between clopidogrel and CYP2C19, and 3 track physician receptiveness to a pharmacists recommendation.
The Community Pharmacy Foundation
Funding Since 2002 | Chicago Illinois
Home CPF Insider Terms Like Us On Facebook! Connect with us on LinkedIn Like Us On Facebook!
CPF Grants/Funding About Us Privacy
Pharmacy Reference Library Contact Us  
© 2017 All Rights Reserved | ISADEX Corporation | Stoughton, WI USA Community Pharmacy Foundation